Sanara Ebitda vs Net Income Analysis
| SMTI Stock | USD 36.34 0.22 0.60% |
Sanara Medtech financial indicator trend analysis is much more than just breaking down Sanara Medtech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sanara Medtech is a good investment. Please check the relationship between Sanara Medtech Ebitda and its Net Income accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanara Medtech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide.
Ebitda vs Net Income
Ebitda vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sanara Medtech Ebitda account and Net Income. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Sanara Medtech's Ebitda and Net Income is 0.45. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Net Income in the same time period over historical financial statements of Sanara Medtech, assuming nothing else is changed. The correlation between historical values of Sanara Medtech's Ebitda and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Sanara Medtech are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Ebitda i.e., Sanara Medtech's Ebitda and Net Income go up and down completely randomly.
Correlation Coefficient | 0.45 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Ebitda
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Sanara Medtech financial statement analysis. It represents the amount of money remaining after all of Sanara Medtech operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from Sanara Medtech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sanara Medtech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanara Medtech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide.As of now, Sanara Medtech's Selling General Administrative is increasing as compared to previous years. Tax Provision is expected to grow at the current pace this year, while Issuance Of Capital Stock is projected to decrease to under 982.1 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 24.1M | 45.8M | 65.0M | 68.2M | Interest Expense | 711.0 | 284.7K | 475.8K | 499.6K |
Sanara Medtech fundamental ratios Correlations
Click cells to compare fundamentals
Sanara Medtech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sanara Medtech fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 11.1M | 9.8M | 36.4M | 61.0M | 73.9M | 77.6M | |
| Short Long Term Debt Total | 2.1M | 481.4K | 425.4K | 819.2K | 11.8M | 12.4M | |
| Other Current Liab | 2.2M | 2.8M | 5.0M | 10.8M | 10.5M | 11.0M | |
| Total Current Liabilities | 2.6M | 3.5M | 6.0M | 12.8M | 13.8M | 14.5M | |
| Total Stockholder Equity | 6.6M | 6.2M | 30.6M | 41.8M | 44.8M | 47.1M | |
| Property Plant And Equipment Net | 790.2K | 1.1M | 2.0M | 2.2M | 3.3M | 3.4M | |
| Net Debt | (4.5M) | 26.0K | (18.2M) | (8.1M) | 6.6M | 7.0M | |
| Retained Earnings | (2.7M) | (7.0M) | (15.2M) | (23.4M) | (28.0M) | (29.4M) | |
| Accounts Payable | 337.5K | 494.8K | 594.0K | 1.4M | 2.0M | 2.1M | |
| Cash | 6.6M | 455.4K | 18.7M | 9.0M | 5.1M | 5.4M | |
| Non Current Assets Total | 2.3M | 5.3M | 11.8M | 40.4M | 54.9M | 57.6M | |
| Non Currrent Assets Other | (2.3M) | (5.3M) | (11.8M) | (40.4M) | (19.0M) | (18.1M) | |
| Cash And Short Term Investments | 6.6M | 455.4K | 18.7M | 9.0M | 5.1M | 5.4M | |
| Net Receivables | 1.3M | 2.3M | 3.0M | 7.0M | 8.5M | 9.0M | |
| Common Stock Shares Outstanding | 2.1M | 5.7M | 7.3M | 7.9M | 8.3M | 8.7M | |
| Liabilities And Stockholders Equity | 11.1M | 9.8M | 36.4M | 61.0M | 73.9M | 77.6M | |
| Non Current Liabilities Total | 2.1M | 446.1K | 222.2K | 6.5M | 15.5M | 16.3M | |
| Other Current Assets | 161.9K | 611.8K | 917.3K | 1.1M | 608.4K | 638.8K | |
| Other Stockholder Equity | (2.1M) | 13.2M | 45.9M | 65.2M | 72.9M | 76.5M | |
| Total Liab | 4.7M | 4.0M | 6.2M | 19.3M | 29.3M | 30.7M | |
| Total Current Assets | 8.9M | 4.5M | 24.6M | 20.6M | 19.0M | 20.0M | |
| Short Term Debt | 117.5K | 251.2K | 406.6K | 627.9K | 1.3M | 762.3K | |
| Common Stock | 3.6K | 6.3K | 7.7K | 8.3K | 8.5K | 8.1K | |
| Inventory | 746.5K | 1.1M | 2.0M | 3.5M | 4.7M | 5.0M | |
| Common Stock Total Equity | 236.6K | 3.6K | 6.3K | 8.3K | 9.5K | 9.1K | |
| Property Plant And Equipment Gross | 790.2K | 1.1M | 2.4M | 3.0M | 4.4M | 4.7M | |
| Intangible Assets | 1.5M | 3.1M | 4.7M | 31.5M | 44.9M | 47.2M | |
| Net Tangible Assets | (6.2M) | 3.1M | 25.9M | 6.7M | 7.7M | 8.1M | |
| Property Plant Equipment | 790.2K | 1.1M | 2.0M | 1.4M | 1.6M | 1.7M | |
| Net Invested Capital | (3.3M) | 6.2M | 30.6M | 41.8M | 54.5M | 57.3M | |
| Net Working Capital | 6.2M | 942.4K | 18.6M | 7.8M | 5.2M | 6.2M | |
| Capital Stock | 11.4M | 6.3K | 7.7K | 8.3K | 8.5K | 8.1K |
Currently Active Assets on Macroaxis
When determining whether Sanara Medtech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanara Medtech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanara Medtech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanara Medtech Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanara Medtech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanara Medtech. If investors know Sanara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanara Medtech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 9.241 | Quarterly Revenue Growth 0.352 | Return On Assets (0.05) | Return On Equity (0.20) |
The market value of Sanara Medtech is measured differently than its book value, which is the value of Sanara that is recorded on the company's balance sheet. Investors also form their own opinion of Sanara Medtech's value that differs from its market value or its book value, called intrinsic value, which is Sanara Medtech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanara Medtech's market value can be influenced by many factors that don't directly affect Sanara Medtech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanara Medtech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanara Medtech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanara Medtech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.